Tuesday, August 23, 2016

Tuesday's New StockGoodie Penny Stock $GRCU - Green Cures & Botanical Distribution Inc.









GRCU - Green Cures & Botanical Distribution Inc.


 

Company Overview


Green Cures & Botanical Distribution Inc., is a development stage company that wholesales and retails hemp-infused nutritional, botanical, sports, and body care products. The company is currently Web-based and focuses on online retailing. Green Cures & Botanical Distribution Inc., operates a diverse portfolio of products and services within the botanical and cannabis industry, as permitted by law. From concept to production and distribution, Green Cures & Botanical Distribution Inc., is continuously creating and introducing products that promote a healthy life style.

Green Cures & Botanical Distribution Inc. (GRCU) develops, produces & distributes premium hemp based products in the following categories: Medical, Skin Care, Beauty, Fashion and lifestyle goods branded under the Original Hollywood Hemp™ brand. Green Cures & Botanical Distribution Inc. (GRCU) also develops beverages branded under the Iconic Beverages ™.





Green Cures & Botanical Distribution Inc. (GRCU) is made up of two divisions:

Original Hollywood Hemp™ : Hemp activated Health, beauty, skin care, hair care, spices, fashion, food products and beverages with the active ingredients of hemp.

Iconic Beverages™ : Beverage division includes in development Hemp infused and no hemp infused beverages which will feature iconic celebrities with exclusive licenses owned by (GRCU) and its shareholders.

Original Hollywood Hemp™ is positioned to be a leader in the multi-Billion dollar industry of Cannabis based products. By reaching its customers in the following categories medical, skin care, beverage & wellness supplements industries, Original Hollywood Hemp™ will also launch celebrity branded products in the summer of 2016.

?By providing our customers direct access to our products through online ordering, we will be able to fulfill orders quickly nationwide where permitted.

?Cannabis is the fastest-growing industry in the United States and Cannabis & Hemp industry is rapidly growing world wide. The demand for high quality products is extreme, through extensive lab testing, Original Hollywood Hemp™ will deliver consistent premium products.

One of the growing segments in the nutritional products industry is Hemp. The international growth of the Hemp industry is attracting millions of new customers annually.


Green Cures & Botanical Distribution Inc. Products


Original Hollywood Hemp™ launches it's skin care and beauty collection, directly to consumers beginning this Summer 2016. The product line consists of hemp infused soaps, beauty products, hemp oil based skin balms, hemp lip balms and wellness products. The line will be expanding as the company grows. Targeting the multi billion dollar skin care and natural healthcare industries under its Original Hollywood Hemp™ brand. From body scrubs, skin lotions, facial and body lotions using the very powerful omega-3 anti aging formulas found in Hemp Oils, a series of in demand beauty products and anti aging products will be created.

Health & Beauty


Original Hollywood Hemp™ Hemp Soap Aqua Blue "Handmade" are infused with Hempseed Oil, Coconut, Grapeseed, and Almond Oils, Shea Butter, Vitamin E, and Glycerin to quench your skin. This product also provides many healing properties for a wide range of skin issues. Holds moisture in skin to protect against our daily exposure to our elements. Provides a natural sunscreen. Essential oil Fragrance is Aqua Blue. Each Soaps are a handmade product, each one is unique in color and pattern, pieces may vary.


Original Hollywood Hemp™ Hemp Soap Heaven Scent"Handmade" Heaven Scent Soap are infused with Hemp seed Oil, Coconut, Grape seed, and Almond Oils, Shea Butter, Vitamin E, and Glycerin to quench your skin. This product also provides many healing properties for a wide range of skin issues. Holds moisture in skin to protect against our daily exposure to our elements. Provides a natural sunscreen. Which are handmade product. Each one is unique in color and pattern, pieces may vary. Essential oil Heaven Scent is Lilly of the valley, Wild Strawberry, Musk, Grapefruit an Sandalwood.


Original Hollywood Hemp™ Hemp Soap Island Fruit "Handmade" are infused with Hemp seed Oil, Coconut, Grape seed, and Almond Oils, Shea Butter, Vitamin E, and Glycerin to quench your skin. This product also provides many healing properties for a wide range of skin issues. Holds moisture in skin to protect against our daily exposure to our elements. Provides a natural sunscreen. Which are a handmade product. Each one is unique in color and pattern, pieces may vary. Essential oil fragrance is Island Fruit.


Original Hollywood Hemp™ Natural Lotion Bar naturally heals with Hempseed Oil, Shea Butter, Almond Oil, Grapeseed Oil, Coconut Oil and Natural Beeswax. Effective moisture for all types of skin, preventing dryness, skin rashes, premature aging, wrinkles and dry cracking fingers and hands. Lotion Bar melts slightly when rubbed against the warmth of your skin, leaving a layer of moisture that softens, heals and protects naturally chemical free.. Easy push up tube.


Original Hollywood Hemp™ Lip Balm Berry are made from all natural ingredients such as Hemp seed oil, Acai Butter, Shea Butter, Coconut Oil, Sweet Almond Oil and natural refined Beeswax. Beeswax seals in all natural oils for long lasting healing and protection. Acai Butter has 10 times more antioxidants than red wine.


Original Hollywood Hemp™ Dissolving Sugar Cubes Cloud 9, cubes scrubs are loaded with Hempseed oil, Coconut, Grapeseed oil, Shea Butter, Vitamin E, and Almond Oil made with pure cane sugar to polish and exfoliate. This product rinses clean and leaves your skin soft and smooth.


Original Hollywood Hemp™ Wild Cherry Lip Balm our balms are made from all natural ingredients such as Hemp seed oil, Shea Butter, Acai Berry Butter, Coconut Oil, Sweet Almond Oil natural refined Beeswax. Beeswax seals in all natural oils for long lasting healing. Choose you skull pattern.

Coming Summer 2016

Green Cures & Botanical Distribution (GRCU) owns a number of celebrity branded beverages that some will utilize hemp infused ingredients, and others will not. Green Cures & Botanical Distribution Inc. (GRCU) plans on launching them in the Summer 2016. Some of these beverages will be branded with internationally known famous sports stars and rock legends. Additionally company is positioned to leverage its celebrity branded beverages produced through its ICONIC Beverages Collection.


Green Cures & Botanical Distribution Inc. (GRCU) introduces an all-new tropical punch flavored energy shot With Legendary Boxer Roberto Duran

Drink specs:

Green Tea • Green Coffee Bean • Acai • Pomegranate ,Vitamin C, Vitamin B12 Branched Chain, Amino Acids including:L Leucine, L Valine, L Isoleucine, Magnesium, Potassiu, Sodium & Chloride, Hemp Oil, ( hemp oil from Original Hollywood Hemp™)


Green Cures and Botanical Distribution Inc. (GRCU) introduces an all-new Berry flavored relaxation shot with Legendary Boxer Roberto Duran.

Drink specs:

Melatonin, Chamomile, Magnesium, L-Theanine, Tryptophan, Sodium Benzoate, Potassium Sorbate
Hemp Oil ( hemp oil from Original Hollywood Hemp™ )



Financials & Filings
Visit: http://www.otcmarkets.com/stock/GRCU/company-info to see complete details.



News Disclaimer:
Press Releases have not been investigated by StockGoodies LLC, therefore we have no idea if the content of this news is based on Fact or Fiction. Although the link for the following press release may be from a familiar and reputable news source, you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. StockGoodies LLC will not be held responsible for any news release, including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.

Jul 26, 2016
Green Cures & Botanical Distribution Announces Hollywood Hemp

Jul 18, 2016
Green Cures & Botanical Distribution Announces Final Negotiations for 20 Acres of Agricultural Land

Jul 14, 2016
Green Cures & Botanical Distribution Inc. Announces Roberto Duran Champion Energy Shot.

Jul 7, 2016
Green Cures & Botanical Distribution Announces Important Shareholder Update


GRCU TEAM

Joe Tragesser - Chief Executive Officer

Joe Tragesser having over 29 years experience with Hostess Brands as a District Sales Manager, then becoming Vice President of Marketing. Also becoming Director of Sales for BCU Food Brokers and currently serves as President for Continental Food & Beverage Brokers. As District Manager, Joe has established long term relationships with key chains such as Ralphs, Food 4 Less, Stater Brothers, Costco, Wal-Mart, Target, Sams Club, Vons, Albertsons, Superior Warehouse to name a few. He has also worked closely with C-Store accounts such as 7-11, Circle K, and Arco AmPm.

Michael Lajtay- Chief Operations Officer – GRCU

Mr. Michael Lajtay is a veteran of the consumer product industry and an accomplished entrepreneur. He is the owner of numerous trademarks registered with the US Patent and Trademark Office, including “Jugular®”, “Go for the Jugular®”, “Takedown®” and “Hole-In-One®”, among others. He is the exclusive licensee of UFC Hall of Fame Inductee and 4 Time Heavyweight Champion Ken Shamrock for beverages. In 2001, Mr. Lajtay obtained the endorsement of Pro Football Hall of Fame Inductee and Super Bowl XXIX MVP Steve Young for his Jugular® Energy Drink, which debuted strongly in 75 Wal-Mart locations. He also produced the “Jugular® Street Luge Racing” video game under an exclusive license with Activision. Also was a founding management team of Vector Aeromotive Corporation – manufacturers of the Vector W8 Twin-Turbo Exotic Sports Car. Vector was 1 of only 4 publicly traded automobile manufacturers in the USA at the time.


Contact


11222 S La Cienega Blvd
Unit B
Inglewood, CA 90304
Phone: 888 509 8085
Email: info@instepholdingsllc.com



Goodies Newsletter Sign Up http://www.stockgoodies.com

WANT A QUICKER WAY TO GET OUR ALERTS?

TEXT "Stock" to 31279

Follow Us on Twitter

Follow Us on Facebook

Follow Us on PennyStockTweets

Contact Us admin@stockgoodies.com

Tuesday, February 9, 2016

Penny Stock AGHI - Agora Holdings Inc.



AGHI - Agora Holdings Inc. 



Company Overview

Website: http://www.geeglemedia.ca/

Agora Holdings is a holding company with interests in the media and software applications. Through its wholly-owned subsidiary, Geegle Media, Agora is dedicated to deliver media products to fulfill the growing needs for social, TV on Demand, data storage applications and other optimizing software solutions.

Company was established in 2010. Main company activity is software development and media applications. Geegle media had developed video software for web TV. In 2012 Geegle media made a contract to use domain name www.geegle.tv

Under that domain was developed interface to service Canada, USA and Europe. Currently under construction is USA.
Other Geegle Media incentives are web development and billing software for Voip applications, mainly web based.

In 2013 Geegle media established office in Bulgaria, where all IT development was outsourced. Currently under development are various web sites concentrated on social networks and data collection.

In 2015 Company is entering into online TV distribution in Canada. Pending an application for online TV license by CRTC





AGHI Websites

Geegle TV On Demand (Canadian)



Watch your favorite movies, tv shows, news, shows, sports and more on Geegle TV On Demand.



Bespoke Web Products - Best Business Investment

A customized experience, tailored to perfection with personal attention.

What the human mind can create and how all of us can benefit from those innovations and brilliant creations. This is what they develop. Tools that can help those in need to Safe time, Improve performance, Publish faster, Talk louder, Laugh longer.

1000 Salads



Reality TV



Lobby TV





Financials & Filings
Visit: http://www.otcmarkets.com/stock/AGHI/company-info to see complete details.





News Disclaimer:
Press Releases have not been investigated by StockGoodies LLC, therefore we have no idea if the content of this news is based on Fact or Fiction. Although the link for the following press release may be from a familiar and reputable news source, you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. StockGoodies LLC will not be held responsible for any news release, including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.

Marketwired (Mon, Feb 8)
Agora Holdings Inc.'s Geegle Media Set to Release FRAME This Month
http://finance.yahoo.com/news/agora-holdings-inc-geegle-media-145524196.html

Marketwired (Tue, Jan 26)
Agora Holdings, Inc. (AGHI) CEO Featured in Exclusive QualityStocks Interview
http://finance.yahoo.com/news/agora-holdings-inc-aghi-ceo-133000155.html

Marketwired (Tue, Jan 12)
Agora Holdings, Inc. (AGHI) Announces Engagement of QualityStocks Corporate Communications Suite
http://finance.yahoo.com/news/agora-holdings-inc-aghi-announces-133000711.html

Marketwired (Thu, Nov 12)
Agora Holdings, Inc.'s Geegle Media Develops TECH, a Workflow Management Software
http://finance.yahoo.com/news/agora-holdings-inc-geegle-media-160000312.html



Contact



Head Office Canada
170 Rimrock rd, Unit #2
North York, ON M3J 3A6
TEL: 1.855.561.4541

USA
1255 W. Rio Salado Parkway
Ste. 215, Tempe, AZ 85281
Tel: 1.844.625.8896
info@agoraholdings.com





Goodies Newsletter Sign Up http://www.stockgoodies.com

WANT A QUICKER WAY TO GET OUR ALERTS?


TEXT "Stock" to 31279


Follow Us on Twitter
http://twitter.com/StockGoodies


Follow Us on Facebook
http://www.facebook.com/groups/STOCKGOODIES


Follow Us on PennyStockTweets
http://www.pennystocktweets.com/profile/StockGoodies

Contact Us admin@stockgoodies.com

Thursday, January 14, 2016

StockGoodie Nasdaq IMNP - Immune Pharmaceuticals Inc.















IMNP - Immune Pharmaceuticals Inc.
  

Company Overview

Website: http://www.immunepharma.com/

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.

The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma.

The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells.

The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors.

Immune is headquartered in the U.S., with its primary research and development facilities in Israel.

Immune Pharmaceuticals Inc (NASDAQ:IMNP) Receives Consensus Rating of “Strong Buy” from Brokerages
January 12th, 2016


Immune Pharmaceuticals Inc (NASDAQ:IMNP) has earned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus price objective of $6.38 for the company and are forecasting that the company will post ($0.16) EPS for the current quarter, according to Zacks. Zacks has also given Immune Pharmaceuticals an industry rank of 75 out of 265 based on the ratings given to its competitors. Read Full Article Here
http://www.americanbankingnews.com/2016/01/12/immune-pharmaceuticals-inc-nasdaqimnp-receives-consensus-rating-of-strong-buy-from-brokerages/






Product Pipeline

Bertilimumab



NanomAbs



AmiKet™

WHAT IS NEUROPATHIC PAIN?

Neuropathic pain describes a group of symptoms caused by damage to nerves. Central neuropathic pain may occur when nerves within the brain or spinal cord are damaged, for example spinal cord injuries, multiple sclerosis and strokes.

However, peripheral neuropathic pain is much more common and results from damage to nerves outside of the brain and spinal cord. These peripheral nerves carry sensations (feeling) to the brain and control the movement of our arms and legs. They also control the bladder and bowel.

HOW IS NEUROPATHIC PAIN TREATED?

Neuropathic pain can be very difficult to treat with only 40-60% of patients achieving partial relief.

Treatments currently used to treat neuropathic pain include local anesthetic patches (lidocaine), anti-depressant medicines (e.g., duloxetine and amitryptiline), anti-convulsants (e.g., pregabalin, gabapentin and carbamazepine) or opioids for severe, chronic pain.

WHAT IS THE RATIONALE FOR USING AMIKET IN NEUROPATHIC PAIN?

AmiKet contains a combination of amitriptyline and ketamine in a topical formulation.

The combination of amitriptyline and ketamine in a cream have been shown to synergistically act to relieve neuropathic pain at the local level.





Cancer Therapeutics

CrolibulinTM

CrolibulinTM is a novel small molecule vascular disrupting agent, or VDA, and apoptosis inducer for the intended treatment of patients with solid tumors. Crolibulin is being studied by the National Cancer Institute in a Phase II study for the treatment of anaplastic thyroid cancer (“ATC”). Crolibulin TM has shown promising vascular targeting activity with potent anti-tumor activity in pre-clinical in vitro and in vivo studies and in a Phase I clinical trial. To date over 100 patients have received Crolibulin TM,

The molecule has been shown to induce tumor cell apoptosis and selectively inhibit growth of proliferating cell lines, including multi-drug resistant cell lines. Murine models of human tumor xenografts demonstrated Crolibulin TM inhibits growth of established tumors of a number of different cancer types. In preclinical animal tumor models, combination therapy has demonstrated synergistic activity with cytotoxic drugs as well as anti-angiogenic drugs, such as Avastin. This may support further development of Crolibulin TM in a variety of cancers other than ATC, including but not limited to refractory ovarian cancer and neuro-endocrine tumors.

Azixa® (verobulin)

Azixa® (verobulin) is a Vascular Disruptive Agent in development for the treatment of primary brain cancers and metastatic tumors with brain involvement. Azixa® is a novel small molecule drug candidate that acts as a microtubule destabilizing agent, causing arrest of cell division and programmed cell death, or apoptosis, in cancer cells. Several currently marketed clinically effective drugs share the identical mechanism of action. Importantly, however, Azixa® has two distinguishing characteristics. In non-clinical studies, Azixa® has demonstrated the unique ability to effectively cross the blood-brain barrier and reach concentrations in the brain which are as much as 30 times that measured in the plasma. In addition, Azixa® does not appear to be subject to multiple drug resistance (MDR) mechanisms.

Two Phase 2a clinical studies demonstrated that:


Azixa®, in combination with standard chemotherapy, resulted in durable responses with no additive toxicity in patients with glioblastoma multiforme (GBM) or metastatic melanoma.

Azixa® in monotherapy resulted in durable responses in GBM patients who had failed both first and second line therapy.

Azixa® has received orphan drug status in the U.S. for the treatment of glioblastoma multiforme (GBM).
 


Strategic Partners

Yissum is the technology transfer company of the Hebrew University of Jerusalem (HU).The University's range of intellectual property includes inventions and know-how in many fields, including nanotechnology, medicine and pharmaceuticals, agriculture and nutrition, water and environmental technologies, computer science, homeland security, and more. Over the past 40 years, Yissum has granted more than 450 technology licenses and is responsible for commercializing an array of successful products that generate over $1 billion in worldwide sales every year. More than 60 spin-off companies, including Mobileye, Keryx, Nasvax, and Novagali have had their start at Yissum. More information is available on Yissum's website.

iCo Therapeutics Inc. trades on the TSX Venture Exchange. Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. Immune Pharmaceutical has licensed Bertilimumab (iCo-008) for systemic uses. Bertilimumab is a human monoclonal antibody targeting eotaxin-1 (eotaxin). The drug was originally developed by Cambridge Antibody Technology (now MedImmune, the biologics division of AstraZeneca) .iCo Therapautics licensed in the drug from CAT before granting Immune an option to in-license bertilimumab for non-ophthalmic indications. iCo retains the rights for the ophthalmic indications. More details can be found on their website, iCoTherapeutics.com.

IMMUNE has licensed the GS system from Lonza for the manufacturing process of Bertilimumab, planning several GMP batches including one in 2012 in anticipation of phase II clinical trials. Headquartered in Basel, Switzerland, Lonza's approach is to provide broad development and manufacturing package to their customers. Publically traded on the Zurich Stock Exchange, Lonza is one of the world leaders in contract manufacturing of monoclonal antibodies and recombinant proteins using mammalian cell culture. This program was established over 25 years ago, just one of many paths the company has followed since its founding in 1897. Please visit Lonza.com for more information on the company.

Financials & Filings
Visit: http://finance.yahoo.com/q?s=IMNP





News Disclaimer:
Press Releases have not been investigated by StockGoodies LLC, therefore we have no idea if the content of this news is based on Fact or Fiction. Although the link for the following press release may be from a familiar and reputable news source, you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. StockGoodies LLC will not be held responsible for any news release, including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.

PR Newswire(Tue, Jan 12)
Immune Pharmaceuticals Announces 2016 Immuno-Oncology Plan
http://finance.yahoo.com/news/immune-pharmaceuticals-announces-2016-immuno-130000289.html

PR Newswire(Mon, Jan 4)
Immune Pharmaceuticals Announces New Data with Topical Cyclosporine Nano-Capsules in Dermatology
http://finance.yahoo.com/news/immune-pharmaceuticals-announces-data-topical-130000739.html

PR Newswire(Mon, Dec 28)
Immune Pharmaceuticals Announces Exclusive License to a Novel Bispecific Antibody Technology
http://finance.yahoo.com/news/immune-pharmaceuticals-announces-exclusive-license-130000883.html\

PR Newswire(Mon, Dec 14)
Immune Pharmaceuticals Announces New Data with Bi-Specific Antibody
http://finance.yahoo.com/news/immune-pharmaceuticals-announces-data-bi-123000256.html

PR Newswire(Wed, Dec 9)
Immune Pharmaceuticals CEO Updates Shareholders On Company Progress
http://finance.yahoo.com/news/immune-pharmaceuticals-ceo-updates-shareholders-135300932.html



Contact



USA Offices – 430 East 29th Street
Suite 940
New York, NY 10016
Tel: 646-440-9310 | eFax:( 1)917-398-1915

Israel Offices – 11C Galgale Haplada (1st Floor)
Herzliya-Pituach, 46722, Israel.
Tel: +972 9 886-6612 | Fax:+972 9 886-6613





Goodies Newsletter Sign Up http://www.stockgoodies.com

WANT A QUICKER WAY TO GET OUR ALERTS?


TEXT "Stock" to 31279


Follow Us on Twitter
http://twitter.com/StockGoodies


Follow Us on Facebook
http://www.facebook.com/groups/STOCKGOODIES


Follow Us on PennyStockTweets
http://www.pennystocktweets.com/profile/StockGoodies

Contact Us admin@stockgoodies.com